ClinicalTrials.gg

Program

divozilimab

Also written as “Divozilimab”.

Its studies are mostly in Scleroderma, Systemic · Multiple Sclerosis · Neuromyelitis Optica, led by Biocad.

Furthest: phase 3, since Feb 3, 20234 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biocad43 open or runningphase 3since Feb 3, 2023Feb 3, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2023First studies: 2 phase 3 studiesFirst studyNCT05726630, NCT05730699
  2. May 16, 2025Phase 3 study in Multiple SclerosisNCT06987851 · 44 enrolled · Russian Federation
  3. Aug 8, 2025Phase 1 study in Systemic Lupus ErthematosusNCT07136389 · 135 planned · Russia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07136389Systemic Lupus Erthematosus · Russia1RecruitingJan 1, 2026135
NCT06987851Multiple Sclerosis · Russian Federation3CompletedMay 16, 202444
NCT05730699Neuromyelitis Optica · Russian Federation3Active, not recruitingJan 2025105
NCT05726630Scleroderma, Systemic · Russia3Active, not recruitingOct 1, 2024152

How it is read

Names in the registry

  • “Divozilimab”, 3 entries
  • “divozilimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.